Loading…
← CockpitCompetitor Analysis › 300573.SZ Shenyang Xingqi Pharmaceutical Co., Ltd. Class AOpen in the cockpit ↗

Shenyang Xingqi Pharmaceutical Co., Ltd. Class A300573.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Chinese ophthalmology drugmaker best known for low-dose atropine eye drops used to slow myopia progression in children.

≈ A small, eye-drops-only Bausch + LombMomentum strong 62
Mkt cap
$1.83B
US dollars, full cap
Free float
100%
of shares outstanding
$/day
$30.6M
20-day average traded
Fwd P/E
13.0×
forward earnings
ROIC−WACC
+33.1 pp
WACC 9.4%
Hurdle
-24 pp
Req g minus delivered
Next earnings
155 days
22 Apr 2027
Close · CNYCN¥34.79
1D+2.2%
1W-0.6%
1M+2.5%
3M-17.3%
6M-24.8%
YTD-28.2%
1Y-34.3%
ATR %3.1%
52w lowhigh41.0% off high

What Shenyang Xingqi Pharmaceutical does

Chinese ophthalmology drugmaker best known for low-dose atropine eye drops used to slow myopia progression in children.

Sells through hospital eye departments and pharmacies, where the main drug is a prescription atropine eye drop that children use to slow myopia (short-sightedness). Because treatment is a long course, repeat purchases drive sales. Other ophthalmic generics go through the same channels.

In one line: A small, eye-drops-only Bausch + Lomb.

Products and services

  • Atropine eye drops (myopia control)
  • Other ophthalmic generics
  • Eye-care OTC products

Customers

  • Hospitals and eye clinics
  • Retail pharmacies

Where it sits in the supply chain

  • Pharmaceuticals
  • Ophthalmology
  • Prescription eye drops

What could go right

  • Rising childhood myopia rates in China
  • Prescription penetration of atropine drops

What could go wrong

  • Compounding-pharmacy competition
  • Provincial tender price cuts

Moat: narrow (regulatory licence, brand). Early mover and approval lead in prescription low-dose atropine for pediatric myopia control.

Headquarters: Shenyang, China · Employees: 2,396

Named competitors

Shenyang Xingqi Pharmaceutical at a glance

Size Shenyang Xingqi Pharmaceutical (300573.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.83B, the 1263rd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥34.79 on 18 Nov 2026.

Performance Over six months the shares fell 24.8%, against -4.7% for the median peer and -20.0% for the China market (cap-weighted) — 3rd lowest of 21 in its peer set.

Growth Revenue grew 16.6% over the last twelve months (peer median +7.8%); the operating margin is 32.9% (peer median 12.7%).

Valuation It trades at 13.0× forward earnings against a peer median of 18.9× (6th cheapest of 19).

Price implies For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is +29%, so the hurdle is -24 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 33.1 points above its cost of capital (9.4% WACC).

Next results Next results expected around 22 Apr 2027 (exchange calendar; dates can move).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026Peer median 97300573.SZ 76
Six months, rebased to 100: Shenyang Xingqi Pharmaceutical against the median of its 20 peers (local-currency closes).

Shenyang Xingqi Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥2.81BCN¥2.45BCN¥1.92BCN¥1.46BCN¥1.24B
Revenue growth—+27%+32%+18%—
Gross profitCN¥2.37BCN¥1.94BCN¥1.47BCN¥1.09BCN¥950M
EBITDAn/aCN¥920MCN¥513MCN¥349MCN¥304M
Net incomeCN¥802MCN¥696MCN¥338MCN¥240MCN¥212M
Free cash flowCN¥614MCN¥483MCN¥218MCN¥55.6M-CN¥13.0M
Capital expenditureCN¥277MCN¥271MCN¥199MCN¥262MCN¥299M
Total debtCN¥106MCN¥101MCN¥232MCN¥91.1MCN¥26.0M

Quarterly statements and history in the cockpit →

Shenyang Xingqi Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%-20%-10%0%+10%605507000028ZYMEDMP000908RARE3010150023993933COHANCEETON600664300009PFIZERAGIOALIVUSSHILPAMED05124540300573.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Shenyang Xingqi Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%0×50×100×150×605507000028ZYMERARE3010150023993933COHANCEETON600211300009PFIZERSHILPAMED300573.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Shenyang Xingqi Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%+300%0%200%605507000028301015ETON300009300573.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Shenyang Xingqi Pharmaceutical is the large dot.

Shenyang Xingqi Pharmaceutical competitors and peer comparison

Head to head with its named competitors (300573.SZ vs 4536.T vs ALC.SW)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Shenyang Xingqi Pharmaceutical 300573.SZ$1.83B-25%+17%33%13.0×5.4%
Santen Pharmaceutical 4536.T$4.14B+10%+2%16%16.7×-5.0%
Alcon ALC.SW$36.9B+18%+1%12%21.5×12.2%

How Shenyang Xingqi Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Shenyang Xingqi Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure300573.SZPeer medianRank in peer set
1-month return+2.5%+0.1%9th highest of 21
6-month return-24.8%-4.7%3rd lowest of 21
Distance from 52-week high-41.0%-28.3%6th lowest of 21
Revenue growth (TTM)+16.6%+7.8%5th highest of 21
Operating margin32.9%12.7%2nd highest of 21
Forward P/E13.0×18.9×6th cheapest of 19
Growth the price implies (Req g, 7 yrs)5.4%1.2%6th most demanding of 14
Growth delivered (Del g)+29.1%+7.8%2nd highest of 14
Hurdle (Req g minus delivered)-23.7 pp-11.4 pp2nd least demanding of 14
ROIC minus cost of capital+33.1 pp+0.7 pp3rd highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Shenyang Xingqi Pharmaceutical 300573.SZChina$1.83B-25%+17%33%13.0×5.4%+29.1%
Guobang Pharma 605507.SSChina$1.82B-6%+3%12%15.7×-6.0%+7.4%
China National Accord Medicines 000028.SZChina$1.81B-3%0%2%10.8×-9.5%+4.2%
Zymeworks ZYMEUnited States$1.81B+5%+98%17%160.4×n/an/a
Dermapharm DMP.DEGermany$1.85B-29%+2%21%13.2×-3.4%+8.0%
CSPC Hunan Jingfeng Pharmaceutical 000908.SZChina$1.85B-38%+5%-18%n/an/an/a
Ultragenyx Pharmaceutical RAREUnited States$1.81B-24%+16%-64%9.6×n/an/a
Qingdao Baheal Medical 301015.SZChina$1.81B+2%-6%8%21.0×10.1%+5.0%
Shenzhen Hepalink Pharmaceutical 002399.SZChina$1.80B-12%-6%8%25.8×-0.7%+0.5%
United Laboratories International 3933.HKHong Kong$1.80B-20%-13%5%13.0×1.2%+7.8%
Cohance Lifesciences COHANCE.NSIndia$1.87B+7%+14%2%96.3×n/an/a
Eton Pharmaceuticals ETONUnited States$1.79B+226%+101%29%24.6×21.9%+359.6%
Tibet Rhodiola Pharmaceutical 600211.SSChina$1.87B-8%+13%27%12.5×-1.2%+16.7%
Harbin Pharmaceutical 600664.SSChina$1.78B+32%+2%5%19.7×-5.3%+8.2%
Anhui Anke Biotechnology (Group) 300009.SZChina$1.88B-12%-9%30%18.1×8.0%+9.3%
Pfizer PFIZER.NSIndia$1.88B-20%+12%34%21.9×11.2%+2.4%
Agios Pharmaceuticals AGIOUnited States$1.78B+4%+214%-298%n/an/an/a
Alivus Life Sciences ALIVUS.NSIndia$1.90B+36%+8%31%23.8×20.1%+6.2%
Shilpa Medicare SHILPAMED.NSIndia$1.91B+94%+37%21%54.3×n/an/a
Grand Pharmaceutical 0512.HKHong Kong$1.93B-25%+7%13%9.4×1.2%+14.1%
Tsumura & 4540.TJapan$1.93B+6%+13%18%10.4×n/an/a

Questions

Who are Shenyang Xingqi Pharmaceutical's main competitors?
Named competitors: Zhaoke Ophthalmology (private or unlisted), Santen Pharmaceutical (4536.T), Alcon (ALC.SW). The cockpit's measured peer set (industry) also includes Guobang Pharma (605507.SS), China National Accord Medicines (000028.SZ), Zymeworks (ZYME), Dermapharm (DMP.DE), CSPC Hunan Jingfeng Pharmaceutical (000908.SZ), Ultragenyx Pharmaceutical (RARE).
Is Shenyang Xingqi Pharmaceutical expensive compared with its peers?
On forward p/e it trades at 13.0× against a peer median of 18.9×, 6th cheapest of 19 in its peer set. For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is +29%, so the hurdle is -24 pp: the price already allows for a slowdown.
How has Shenyang Xingqi Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -24.8% against -4.7% for the median peer; over one year -34.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.